![](https://library.celltelligence.com/wp-content/uploads/2020/07/Novartis-Clinical-Trials.png)
$0
Novartis Ph1b PORTIA Results Presented at Virtual AACR II
On Monday, June 23, Novartis presented (Ulrich Jaeger et al, June 2020) updated clinical data from the Kymriah + pembrolizumab (pembro, a PD-1 inhibitor) Ph1 PORTIA study in ≥3L R/R DLBCL. Below, Celltelligence provides thoughts on the significance of this data, and particularly how it compares to recent CAR-T + checkpoint inhibitor data from Gilead (Yescarta), BMS (Liso-cel), and Autolus (AUTO3).